Pramlintide CAS:151126-32-8

Pramlintide (trade name Symlin) is an injectable amylin analogue drug for diabetes (both type 1 En 2), developed by Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca).Pramlintide is sold as an acetate salt.

Pramlintide is an analogue of amylin, a small peptide hormone that is released into the bloodstream by the β cells of the pancreas along with insulin after a meal.Like insulin, amylin is completely absent in individuals with Type I diabetes.

In synergy with endogenous amylin, pramlintide aids in the regulation of blood glucose by slowing gastric emptying, promoting satiety via hypothalamic receptors (different receptors than for GLP-1), and inhibiting inappropriate secretion of glucagon, a catabolic hormone that opposes the effects of insulin and amylin. Pramlintide also has effects in raising the acute first-phase insulin response threshold following a meal.

Both a reduction in glycated hemoglobin and weight loss have been shown in insulin-treated patients with type 2 diabetes taking pramlintide as an adjunctive therapy.